FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 14, 2004
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (IRS Employer
jurisdiction of (Commission Identification
incorporation) File Number) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS.
On April 14, 2004, DUSA Pharmaceuticals, Inc. ("DUSA") announced that Levulan(R)
Kerastick(R) end-user sales to physicians increased in its first quarter 2004.
DUSA also announced an increase in BLU-U(R) units placed in doctors' offices and
that it participated in the 2004 annual meeting of the American Society of Laser
Medicine and Surgery in Dallas, Texas.
ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.
[99] Press Release dated April 14, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: April 14, 2004 By: /s/ D. Geoffrey Shulman
----------------------------------
D. Geoffrey Shulman, MD, FRCPC
President and Chief Executive
Officer